Literature DB >> 10720586

ET(B) receptor blockade potentiates the pressor response to big endothelin-1 but not big endothelin-2 in the anesthetized rabbit.

J P Gratton1, G A Rae, G Bkaily, P D'Orléans-Juste.   

Abstract

The precursor of endothelin-1, big endothelin-1, is considered to be a more reliable marker of systemic production of vasoactive peptide. However, it is largely unclear whether ET(B) receptor-dependent clearance and endothelium-derived relaxing factors affect the precursor in a similar manner to mature ET-1. These ET(B)-dependent modulations of big ET-1 and big ET-2 pressor properties were therefore studied in the anesthetized rabbit. When injected into the left cardiac ventricle, ET-1 and ET-2 (0.01 to 1 nmol/kg) each induced biphasic responses (a depressor followed by a pressor response), whereas big ET-1 and big ET-2 (0.1 to 3 nmol/kg) caused only protracted pressor responses. The highest dose of big ET-1 caused significantly greater responses than ET-1, ET-2, or big ET-2. A selective ET(A) receptor antagonist, BQ-123 (1 mg/kg), markedly reduced pressor responses to all 4 peptides, whereas blockade of ET(B) receptors with BQ-788 (0.25 mg/kg) sharply potentiated the responses to ET-1, ET-2, and big ET-1, but not to big ET-2. Indomethacin (10 mg/kg) sharply potentiated the pressor response to ET-1 (1 nmol/kg), but not big ET-1, at all time points. In control animals, ET-1, but not big ET-1, also triggered an indomethacin-sensitive increase in circulating prostacyclin. Finally, systemically administered big ET-1, but not big ET-2, induced a phosphoramidon-sensitive increase in plasma IR-ET. Our results suggest a significant limiting role of ET(B) receptors on pressor responses to big ET-1. In contrast, the same receptor entities do not modulate the hemodynamic properties of the ET-2 precursor, given that, unlike big ET-1, it is poorly converted in the pulmonary or systemic circulation in anesthetized rabbits.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720586     DOI: 10.1161/01.hyp.35.3.726

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Enzymatic pathways involved in the generation of endothelin-1(1-31) from exogenous big endothelin-1 in the rabbit aorta.

Authors:  Carlos R Tirapelli; Marie-Helene Fecteau; Jean-Claude Honore; Eurode Legros; Fernand Gobeil; Pedro D'Orleans-Juste
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

Review 2.  Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer.

Authors:  Lowell Ling; Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

3.  Role of endothelin ET(A)- and ET(B)-receptors in haemodynamic compensation following haemorrhage in anaesthetized rats.

Authors:  Beatriz Palacios; Su Lin Lim; Catherine C Y Pang
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 4.  Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease.

Authors:  Marc Q Mazzuca; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2012-03-30       Impact factor: 5.858

5.  High salt-induced hypertension in B2 knockout mice is corrected by the ETA antagonist, A127722.

Authors:  I Brochu; M Houde; L Desbiens; E Simard; F Gobeil; W Semaan; G Bkaily; P D'Orléans-Juste
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

6.  Activation of ETB receptors regulates the abundance of ET-1 mRNA in vascular endothelial cells.

Authors:  N Farhat; C C Matouk; A M Mamarbachi; P A Marsden; B G Allen; E Thorin
Journal:  Br J Pharmacol       Date:  2008-02-18       Impact factor: 8.739

7.  Big endothelin-1 and nitric oxide in hypertensive elderly patients with and without obstructive sleep apnea-hypopnea syndrome.

Authors:  Iara Felicio Anunciato; Rômulo Rebouças Lobo; Eduardo Barbosa Coelho; Waldiceu Aparecido Verri; Alan Luiz Eckeli; Paulo Roberto Barbosa Evora; Fernando Nobre; Júlio César Moriguti; Eduardo Ferriolli; Nereida Kilza da Costa Lima
Journal:  Arq Bras Cardiol       Date:  2013-08-27       Impact factor: 2.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.